With NASH results, Intercept Pharma will seek approval for first-ever treatment for fatty liver condition
With new clinical trial results, Intercept Pharma will seek approval for first-ever treatment for NASH, a fatty liver condition.
Intercept Pharmaceuticals (ICPT) said Tuesday that an experimental medicine to treat the fatty liver disease known as NASH achieved its primary goal in a Phase 3 clinical trial, giving it a shot at becoming the first drug to treat the condition and turning it into a potential blockbuster commercial opportunity.
Based on the data collected
